HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence Claus Hellerbrand, Andreas Pöppl, Arndt Hartmann, Jürgen Schölmerich, Guntram Lock Clinical Gastroenterology and Hepatology Volume 1, Issue 4, Pages 279-284 (July 2003) DOI: 10.1016/S1542-3565(03)00132-0
Figure 1 Serum ferritin levels in HCC patients with C282Y heterozygote (C282Y +/−) (n = 14) or C282Y wt (C282Y −/−) (n = 83) genotype. Bars represent median serum levels. Clinical Gastroenterology and Hepatology 2003 1, 279-284DOI: (10.1016/S1542-3565(03)00132-0)
Figure 2 Transferrin saturation (TFS) in HCC patients with C282Y heterozygote (C282Y +/−) or C282Y wt (C282Y −/−) genotype. Bars represent median TFS. Clinical Gastroenterology and Hepatology 2003 1, 279-284DOI: (10.1016/S1542-3565(03)00132-0)
Figure 3 Hepatic iron deposition comparing C282Y heterozygote (C282Y +/−) and wt (C282Y −/−) HCC patients. Iron deposition was analyzed in (A) HCC tissue (n = 113) and (B) nontumorous surrounding liver tissue (n = 83) using a semiquantitative histologic score. Clinical Gastroenterology and Hepatology 2003 1, 279-284DOI: (10.1016/S1542-3565(03)00132-0)